# Vor Biopharma Inc. (VOR)

> Source: Nexqual · https://nexqual.com/VOR · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Vor Biopharma Inc. (VOR), nexqual.com/VOR" · informational, not investment advice.

## VOR major shareholder filing: Schedule 13D/A, Jul 21, 2026
RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah filed a Schedule 13D/A on Jul 21, 2026, reporting up to 19.90% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.

Source: https://www.sec.gov/Archives/edgar/data/1817229/000134682426000197/0001346824-26-000197-index.htm

**Price:** USD 20.91 (+1.26% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 20.65 · day 20.66–21.59 · 52w 6.5–26.76 · market cap $1.24B · NMS

## Key facts
- Valuation: P/E 2.0x.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $24.7M; 4 not under a Rule 10b5-1 plan ($24.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 39 (range 27–50).
- Total return with dividends: 1Y -17.4% vs S&P 500 +14.8%; 5Y -93.3% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.72, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: VOR paid no cash dividend in the last five years.
- Short interest: 14.81% of float (as of 2026-10-15), 5.7 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$69.0M | -$93.4M | -$126M | -$121M | -$372M | -$147M |
| Net income | -$68.9M | -$92.1M | -$118M | -$117M | -$696M | $628M |
| EPS (diluted) | -$42.00 | -$46.60 | -$35.00 | -$34.03 | -$70.50 | — |
| Free cash flow | -$73.0M | -$93.6M | -$101M | -$99.9M | -$144M | -$141M |
| Cash + short-term investments | $207M | $230M | $137M | $91.9M | $455M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 2.0x · FCF yield -11.38% · Earnings yield 50.75%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | Ra Capital Management, L.P. |  | 213 | $4K | 0% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-22 | Ra Capital Management, L.P. | Director | 165,150 | $2.6M | 6.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-17…2026-04-20 | Ra Capital Management, L.P. | Director | 630,374 | $10.2M | 19.7% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-13…2026-04-15 | Ra Capital Management, L.P. | Director | 737,989 | $11.9M | 18.8% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 39 (low 27, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | William Blair | Initiated | Outperform |  |
| 2026-08-12 | Wedbush | Target raised | Neutral | $18 → $27 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -17.4% | -93.3% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | -17.5% | -41.8% |
| Volatility (annualized) | 112.8% | 132.3% |
| Max drawdown | -72.6% (Oct 2025→Nov 2025) | -99.2% (Nov 2021→May 2025) |

## Dividends
VOR paid no cash dividend in the last five years.

## Short interest
7,445,537 shares sold short, 14.81% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,904,520 shares (-5.8%). Days to cover: 5.7 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/VOR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in VOR's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/vor-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | RA Capital Healthcare Fund | "For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private…" |
| Customer | Reprogrammed Interchange | "For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private…" |
| Customer | RA Capital Management | "For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private…" |
| Partner | RemeGen | "Pursuant to our license agreement with RemeGen, we were granted an exclusive license to develop and commercialize telitacicept outside of the Greater China region, which includes mainland China, Hong Kong, Macau and Taiw…" |
| Partner | Nicolaus & Company | "In December 2022, we entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated ("Stifel") as the agent (the "Stifel ATM Facility")." |
| Competitor | Johnson & Johnson (JNJ) | "The autoimmune field is a competitive landscape involving multiple fusion protein class members (atacicept, povetacicept), monoclonal antibodies, other biologics, chimeric antigen receptor (CAR) T cells and small molecul…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.72 | $-0.77 | +$0.05 | $0 | 1 |
| Next quarter (ends 2026-12-31) | $-0.77 | $-0.93 | +$0.16 | $0 | 1 |
| Current fiscal year (ends 2026-12-31) | $-6.88 | $-6.90 | +$0.02 | $0 | 2 |
| Next fiscal year (ends 2027-12-31) | $-3.67 | $-3.74 | +$0.07 | $0 | 3 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-12): ±23.0%; last 1 reports averaged ±0.2%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 116.4% | ±23.0% |
| 2026-12-18 | 50 | 103.9% | ±30.3% |
| 2027-02-19 | 113 | 94.4% | ±40.4% |
| 2027-05-21 | 204 | 127.3% | ±70.9% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $307.53 | −$1.19 | Beat +$308.72 | -0.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-14 | Schedule 13G/A | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC: 9.9% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1817229/000123191926000936/0001231919-26-000936-index.htm |
| 2026-08-14 | Schedule 13G/A | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 4.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1817229/000123191926000911/0001231919-26-000911-index.htm |
| 2026-08-13 | Schedule 13G/A | Verve Capital Limited: 6.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1817229/000208834426000009/0002088344-26-000009-index.htm |
| 2026-08-11 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1817229/000119312526343607/0001193125-26-343607-index.htm |
| 2026-08-07 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 12.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1817229/000031506626002253/0000315066-26-002253-index.htm |
| 2026-08-06 | Schedule 13G | FMR LLC, Abigail P. Johnson: 9.1% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1817229/000031506626002174/0000315066-26-002174-index.htm |
| 2026-07-30 | Schedule 13G | BlackRock, Inc.: 5.7% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1817229/000201238326003175/0002012383-26-003175-index.htm |
| 2026-07-21 | Schedule 13D/A | RA Capital Management, L.P., Peter Kolchinsky: 19.9% of shares, 5%+ holder that may seek to influence the company (amended) — “Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the…” | https://www.sec.gov/Archives/edgar/data/1817229/000134682426000197/0001346824-26-000197-index.htm |
| 2026-07-07 | 8-K | Director or executive officer change, or pay arrangement — “(b) Resignation of Andrew Levin, M.D., Ph.D. as a Director On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the "Board") of Vor Biopharma Inc. (the "Company"), delivered his notice of resignation, effective immediately. Dr. Levin's decision to resign was not as a result of any disagreement with the Company. The Board thanks Dr. Levin for his service to the Company. (d) Appointment of David Zaccardelli, Pharm.D., as a Director On July 7, 2026, the Board appointed David Zaccardelli,…” | https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/0001193125-26-297454-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.